Claim: Ivermectin doesn’t protect against Covid
A new very large scale study analysing Brazilian health data says it reduces death by 92%
This article has been added to my comprehensive fact check about Ivermectin, Fact check: Ivermectin doesn't help against COVID-19 (There is a plethora of evidence that it does) You may want to read that.
A new very large scale study analysing Brazilian health data says it reduces death by 92%
This is a great study! It has the longest title I’ve ever seen:
But that’s not why it’s good: it’s a huge, tightly controlled population study looking at the Brazilian data, examining hospitalisations and death rates among Ivermectin non users, irregular uses and regular users.
This study shows that Ivermectin decreased hospitalisations from Covid by 100%, and death by 92%. There was a particularly notable reduction in risk for those with comorbidities, and the study looked at a lot of comorbidities: matched groups by Age, Sex, Race, Type 2 diabetes, hypertension, asthma, Chronic obstructive pulmonary disease (COPD), other respiratory diseases, Cardiovascular diseases, cancer, history of smoking, history of stroke, history of Myocardial Infarction (heart attack). Even irregular use of Ivermectin was helpful in cutting the risk from catching Covid.
What is great about this study is that it is asking a simple question, is highly rigorous and looks at real data, and has a very large group of people that it is looking at. There appears to be no statistical games being played.
Overall risk of death for non users was 17.3 in 10,000, risk of death for irregular users was 8.5 in 10,000 and risk of death for regular users was 2.4 in 10,000. The whole study is worth reading and was done really well.
Here’s their conclusion from the paper:
Conclusion
The regular use of ivermectin decreased hospitalization for Covid-19 by 100%, mortality by 92% and the risk of dying from Covid-19 by 86%, when compared to non-users. Protection from COVID-19 related outcomes was observed across all levels of ivermectin use, with notable reduction for risk of death in the over 50-year-old population and those with comorbidities. The reduction in infection rate was significant, irrespective of level of ivermectin use. The results of this prospective observational study of a strictly controlled population of 223,128 participants reinforce the efficacy of ivermectin and the demonstration of a dose-response effect.

I was alerted to this by a Steve Kirsch article: